Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aslan Pharmaceuticals has entered into an agreement to develop Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase - BMS-777607 - to treat solid tumors.
Subscribe to our email newsletter
Aslan has gained rights to develop and market BMS-777607 in Australia,China, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains rights at the rest of the contries, under the signed agreement.
As per a pre-agreed development agreement, Aslan is set to develop BMS-777607 that will target gastric cancer and lung cancer.
Aslan CEO Carl Firth said this partnership demonstrates how a drug development company can work together with a global biopharmaceutical company to accelerate drug development and conduct early clinical studies in Asia.